Thu 22 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries. | Bayer | Ongoing | Riociguat | 4 | 18303 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) | Bayer | Terminated | Finerenone | 3 | BAY 94-8862 17530 | King Abdulaziz University Hospital (Jeddah) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease | Bayer | Terminated | Finerenone | 3 | BAY 94-8862 16244 | King Abdulaziz University Hospital (Jeddah) |
| "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" | Bayer | Terminated | BAY 80-6946/Copanlisib | 3 | BAY 80-6946 / 17322 | King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | MEDI4736/Paclitaxel | 2 | ESR-14-10649 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) | AstraZeneca | Ongoing | MEDI4736+Tremelimumab | 3 | D419AC00003 | King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions. | SFDA | Completed | Lipitor® lovarst tablet | 4 | 42370 | saudi Ajal |
| RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors | Bayer | Ongoing | Nexavar (Sorafenib) | 4 | 17852 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Treatment Patterns, Outcomes, and Resource Use Study For Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-Squamous)in Kingdom of Saudi Arabia and United Arab Emirates | Bristol-Myers Squibb | Ongoing | - | 4 | CA209454 | King Abdulaziz Medical City NG (Riyadh) |
| SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Roche | Ongoing | N/A | 4 | ML29618 | King Abdulaziz Medical City NG (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.